Metraipolis › archive › dc_db4292d79759

First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial — Europe PMC PMID:41314141

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41314141
DOI
10.1016/j.ebiom.2025.106044
License (as archived)
solo-consultazione
Archived
2026-11-08T05:28:16.968Z
SHA-256 of the archived text
0704941d19b8329cd01cc08e323043329f891ee4280aa316e7825cb9df0cf6a8
Stable URL of this page
https://metraipolis.com/documento/dc_db4292d79759

How to cite

First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial — Europe PMC PMID:41314141 — Europe PMC (en), https://europepmc.org/article/MED/41314141 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_db4292d79759 (Metraipolis archive dc_db4292d79759, sha256 0704941d19b8329cd01cc08e323043329f891ee4280aa316e7825cb9df0cf6a8)
BibTeX
@misc{dcdb4292d79759,
  title = {First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial — Europe PMC PMID:41314141},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41314141},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_db4292d79759; sha256 0704941d19b8329cd01cc08e323043329f891ee4280aa316e7825cb9df0cf6a8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41314141. Agents can read the archived copy with the MCP tool read_document.